Last reviewed · How we verify

Regional Anesthesia for Surgery — Treatment Landscape & Competitive Intelligence

Regional Anesthesia for Surgery (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Regional Anesthesia for Surgery, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Chirocain LEVOBUPIVACAINE Purdue Pharma Lp levobupivacaine Cytochrome P450 2D6 1999-01-01
Naropin ROPIVACAINE Fresenius Kabi Amide Local Anesthetic Sodium channel protein type 5 subunit alpha 1996-01-01
Bupivacaine Hydrochloride Bupivacaine Hydrochloride Pfizer Amide-type local anesthetic Nerve sodium channels 1972-01-01
Bupivacaine Hydrochloride And Epinephrine BUPIVACAINE Innocoll Amide Local Anesthetic Cytochrome P450 2D6 1972-01-01
Duragesic fentanyl Johnson & Johnson (Janssen Pharmaceutica) Synthetic opioid analgesic D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor 1968-01-01
MS Contin morphine sulfate Generic (multiple manufacturers) Opioid analgesic Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor 1941-01-01
Fentanyl (F2) Fentanyl (F2) Oslo University Hospital Synthetic opioid D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor
Bupivacain Bupivacain Sisli Hamidiye Etfal Training and Research Hospital 5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3
Ropivacain Ropivacain University Hospital, Basel, Switzerland Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Naropeine Naropeine University Hospital, Rouen Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Regional Anesthesia for Surgery
  2. Generic (multiple manufacturers) · 1 drug in Regional Anesthesia for Surgery
  3. Innocoll · 1 drug in Regional Anesthesia for Surgery
  4. Johnson & Johnson (Janssen Pharmaceutica) · 1 drug in Regional Anesthesia for Surgery
  5. Oslo University Hospital · 1 drug in Regional Anesthesia for Surgery
  6. Purdue Pharma Lp · 1 drug in Regional Anesthesia for Surgery
  7. Rigshospitalet, Denmark · 1 drug in Regional Anesthesia for Surgery
  8. Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in Regional Anesthesia for Surgery
  9. University Hospital, Basel, Switzerland · 1 drug in Regional Anesthesia for Surgery
  10. Fresenius Kabi · 1 drug in Regional Anesthesia for Surgery
  11. University Hospital, Rouen · 1 drug in Regional Anesthesia for Surgery

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Regional Anesthesia for Surgery:

Cite this brief

Drug Landscape (2026). Regional Anesthesia for Surgery — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/regional-anesthesia-for-surgery. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing